SynthesisEuropean journal of nuclear medicine and molecular imaging2010
Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.
Synthesis in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.The Cochrane database of systematic reviews · 2019Pooled it
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.European journal of nuclear medicine and molecular imaging · 2015Guideline
- F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.Systematic reviews · 2012Pooled it
- Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.European journal of nuclear medicine and molecular imaging · 2010Pooled it
- Review
- 18F-FDG PET/CT Impact on Malignant Melanoma Patients Undergoing Staging and Restaging: A Single-University-Center Experience in a Real-World Setting.Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic Performance of [Cancers · 2024Review
- Whole-Body Imaging for the Primary Staging of Melanomas-A Single-Center Retrospective Study.Cancers · 2023Article
- [Diagnostics (Basel, Switzerland) · 2023Review
- Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.European journal of nuclear medicine and molecular imaging · 2022Article
- Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.Diagnostics (Basel, Switzerland) · 2022Review
- Whole-Body versus Routine Skull Base to Mid-thighJournal of clinical imaging science · 2020Article
- Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.Melanoma research · 2018Article
- Melanoma & nuclear medicine: new insights & advances.Melanoma management · 2018Review
- Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse.European journal of nuclear medicine and molecular imaging · 2018Article
- Evaluation ofNuclear medicine and molecular imaging · 2018Article
- PET Scan Misses Cutaneous Melanoma Metastasis with Significant Tumour Size and Tumour Thickness.Open access Macedonian journal of medical sciences · 2017Article
- Article
- The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients.EJNMMI research · 2016Article
- The Development of a Checklist to Enhance Methodological Quality in Intervention Programs.Frontiers in psychology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this study was to perform a systematic review of the literature to evaluate the accuracy of FDG-PET in staging and restaging of cutaneous melanoma.
methodsSystematic methods were used to identify, select, and evaluate the methodologic quality of the studies as well as to summarize the overall findings of sensitivity and specificity. The search strategy consisted of identifying studies published between 2000 and 2006. Inclusion criteria were studies that evaluated the diagnostic performance of FDG-PET in staging/restaging of cutaneous melanoma. The results were compared and pooled with a meta-analysis published previously that included studies published until 1999. The meta-analysis included 95% confidence intervals (CI) of sensitivity, specificity, likelihood-ratio (LR), and diagnostic-odds-ratio (DOR).
resultsThe quantitative meta-analysis included 24 studies that were analysed in two groups: eight studies were included only in the regional staging analysis (group I), 13 studies were included only in the detection of distant metastases analysis (group II), and three studies were included in both analyses. Compliance with the methodologic-quality criteria was acceptable. We analysed the results of data presented in patients, lesions, basins, lymph-nodes, areas, and scans. Regarding the performance of FDG-PET in the detection of metastases, the pooled studies presented homogeneity for the negative-LR (0.15; 95% CI, 0.10-0.22) when analyzing lesions. When analyzing scans, there was global homogeneity for specificity (0.86; 95% CI, 0.77-0.92), positive-LR (5.86; 95% CI, 3.64-9.43), and DOR (37.89; 95% CI, 15.80-90.86). The pooled studies presented heterogeneity for the other items analysed. Regarding the detection of regional metastases, when analyzing lymph-nodes there was global homogeneity for specificity (0.99; 95% CI, 0.97-0.99; P = 0.101). The meta-regression evidenced that the variable that most influenced the DOR of the different studies and that can explain the heterogeneity was the year of publication; this may be related to the evolution of PET technology and an improvement of sensitivity/specificity.
conclusionFDG-PET is not useful in the evaluation of regional metastases, as it does not detect microscopic disease. However, FDG-PET could be useful in the detection of distant metastases, and could suggest its utility in the management of patients with cutaneous melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.